Loading stock data…
SGMT
$7.40-0.25 (-3.27%)
Market OpenUpdated 1:43 PM EDT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sagimet Biosciences Inc. in the Healthcare sector is trading at $7.44. Wall Street consensus targets $28.50 (10 analysts), implying a +283.0% move over the next 12 months. The stock is currently 35% below its 52-week high of $11.41, remaining 10.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +283.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$7.40
Potential Downside
0%
Whystock Fair Value$7.40
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$28.50+285.1%
Range$8.00 – $49.00
Fundamentals
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$204.63M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-45.82%
Volume
Today's trading volume
372,301
Recent News
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?
The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 241.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise
Sagimet Biosciences (NASDAQ:SGMT) said it is sharpening its strategic focus on developing differentiated therapies for patients with moderate to severe acne, with plans to advance its lead fatty acid synthase (FASN) inhibitor, denifanstat, into a U.S. phase III registrational study in the second hal
Why Sagimet Biosciences Stock Is Soaring Today
The biopharma company confirmed it's still aiming at the United States' acne-treatment market.
Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans
Sagimet Biosciences Inc. (NASDAQ:SGMT) surged 30% on Monday after unveiling plans to launch a Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.